Ascendis Pharma A/S
ASND
214 hedge funds and large institutions have $8.78B invested in Ascendis Pharma A/S in 2024 Q4 according to their latest regulatory filings, with 37 funds opening new positions, 86 increasing their positions, 65 reducing their positions, and 39 closing their positions.
32% more repeat investments, than reductions
Existing positions increased: 86 | Existing positions reduced: 65
1.93% more ownership
Funds ownership: 103.93% → 105.86% (+1.9%)
5% less first-time investments, than exits
New positions opened: 37 | Existing positions closed: 39
2% less funds holding
Funds holding: 219 → 214 (-5)
6% less capital invested
Capital invested by funds: $9.31B → $8.78B (-$536M)
18% less funds holding in top 10
Funds holding in top 10: 17 → 14 (-3)
64% less call options, than puts
Call options by funds: $11.9M | Put options by funds: $32.7M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$126M |
| 2 |
Capital International Investors
Los Angeles,
California
|
+$99.1M |
| 3 |
Morgan Stanley
New York
|
+$67.5M |
| 4 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$52.9M |
| 5 |
Westfield Capital Management
Boston,
Massachusetts
|
+$51.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Spyglass Capital Management
San Francisco,
California
|
-$97.5M |
| 2 |
TCM
TimesSquare Capital Management
New York
|
-$74.8M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$73.3M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$72.7M |
| 5 |
Brown Advisory
Baltimore,
Maryland
|
-$56.7M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BCM
251
Barometer Capital Management
Toronto,
Ontario, Canada
| – | -$150K | -1,004 | Closed |
|
252
Bessemer Group
Woodbridge,
New Jersey
| – | -$109K | -733 | Closed |
|
|
HT
253
Headlands Technologies
Chicago,
Illinois
| – | -$104K | -699 | Closed |
|
|
HI
254
Hoey Investments
Coatesville,
Pennsylvania
| – | -$3.27K | -24 | Closed |
|
ASND Hedge Fund Activity: Q4 2024 in Review
214 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Ascendis Pharma A/S (ASND) for Q4 2024, worth a combined $8.78B — down 5.8% from $9.31B a quarter earlier.
Sellers outnumbered buyers: 39 funds closed out of ASND and 37 opened new positions — a net loss of 2 holders — while 65 trimmed existing stakes and 86 added.
The largest buyer was T. Rowe Price Investment Management, adding an estimated $126M. The largest seller was Spyglass Capital Management, exiting entirely with an estimated $97.5M sold.
- 214 institutional investors held Ascendis Pharma A/S (ASND) as of Q4 2024, down from 219 in Q3 2024.
- Funds reported $8.78B of Ascendis Pharma A/S stock for Q4 2024, down 5.8% quarter-over-quarter.
- 37 funds opened new Ascendis Pharma A/S positions in Q4 2024 and 39 closed out, a net change of -2 holders.
- The largest Ascendis Pharma A/S buyer in Q4 2024 was T. Rowe Price Investment Management, an estimated $126M added.
- The largest Ascendis Pharma A/S seller in Q4 2024 was Spyglass Capital Management, an estimated $97.5M sold.
Based on aggregated 13F filings for Q4 2024.